<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831424</url>
  </required_header>
  <id_info>
    <org_study_id>NYSPI 7424</org_study_id>
    <nct_id>NCT04831424</nct_id>
  </id_info>
  <brief_title>Mitochondrial Stress, Brain Imaging, and Epigenetics</brief_title>
  <acronym>MiSBIE</acronym>
  <official_title>The Mitochondrial Stress, Brain Imaging, and Epigenetics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dartmouth College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universit√§t Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MiSBIE study collects biological, behavioral, psychosocial, neuropsychological, and brain&#xD;
      imaging data in participants with either: normal mitochondrial function, individuals with the&#xD;
      m.3243A&gt;G mitochondrial DNA (mtDNA) mutation, and individuals a single large-scale mtDNA&#xD;
      deletion. These defects induce mitochondrial allostatic load (MAL). The 2-day protocol, plus&#xD;
      home-based data collection, will provide a comprehensive assessment of the multi-systemic&#xD;
      dysregulation associated with MAL or mitochondrial dysfunction, and the link to physical and&#xD;
      mental health-related symptoms.&#xD;
&#xD;
      Aim 1: Determine the influence of MAL on systemic AL biomarkers.&#xD;
&#xD;
      Aim 2: Establish the influence of MAL on stress reactivity profiles.&#xD;
&#xD;
      Aim 3. Examine the association between MAL and psychological functioning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age-related physical and cognitive decline, as well as the risk of neurological diseases, are&#xD;
      increased by the effects of psychosocial stress. Psychosocial stress triggers neuroendocrine,&#xD;
      metabolic, cardiovascular, and inflammatory changes in the body. These changes vary in nature&#xD;
      and magnitude between individuals, and are associated with long-term disease risk. However,&#xD;
      the biological determinants of the stress response are not well understood.&#xD;
&#xD;
      This project aims to translate the preclinical findings (how mitochondria regulate the&#xD;
      different organ systems and major stress response axes are activated during psychological&#xD;
      stress) by studying a population of individuals with varying degree of mitochondrial&#xD;
      dysfunction, and to test potential neural mechanism, and why some individuals respond more&#xD;
      strongly than others to the same stressor.&#xD;
&#xD;
      Each participant will be studied over two consecutive days. Participants will be housed on&#xD;
      campus to standardize study conditions. On Day 1, participants will donate blood and saliva,&#xD;
      undergo a neuropsychological assessment, and complete questionnaires to assess psychosocial&#xD;
      functioning and psychiatric symptoms. After lunch, the investigator will monitor dynamic&#xD;
      changes in mental health-related biological outcomes (positive and negative affect,&#xD;
      circulating levels of the inflammatory cytokine IL-6, and salivary cortisol) in response to a&#xD;
      standardized laboratory challenge. On Day 2, participants will undergo a medical evaluation&#xD;
      to assess clinical symptoms and undergo a whole brain neuroimaging session where both resting&#xD;
      and stress elicited activity will be measured. A variant of the same stressor as on Day 1&#xD;
      will be used in the neuroimaging session. Participants will then be debriefed, concluding the&#xD;
      individuals participation in the study. Participants also complete a home-based saliva and&#xD;
      stool collection to examine diurnal variation in salivary hormones, and to examine microbiome&#xD;
      composition. This translational project will generate a unique combination of complimentary&#xD;
      molecular, cellular, and neuroimaging data that will advance our understanding of the links&#xD;
      between mitochondria, the brain, and mental health-related outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will undergo TSST and have samples With DNA collected (blood plasma and serum, purified leukocytes, saliva, urine, buccal epithelial cells, hair are stored).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average TSST-induced elevation in cortisol</measure>
    <time_frame>Day 1 post challenge (approximately 2 hours)</time_frame>
    <description>This is designed to measure cortisol reactivity to the trier social stress test (TSST), quantified from salivary cortisol (LC-MS) over an 8-timepoints timecourse. The elevation will be measured as the area under the curve (AUC) for the cortisol time course.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average allostatic load index</measure>
    <time_frame>Blood collected on Day 1</time_frame>
    <description>Groups will be compared on a quantitative allostatic load (AL) index integrating baseline fasting measures of neuroendocrine, immune and metabolic systems, urinary catecholamines, hematological measures, and hair/diurnal cortisol levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average TSST-induced elevation in heart rate</measure>
    <time_frame>Day 1 post challenge (approximately 2 hours)</time_frame>
    <description>Groups will be compared on heart rate (HR) as a measure of cardiovascular reactivity to stress, monitored using a continuous 3-lead ECG. The elevation will be computed from the baseline HR to the peak HR reached during the TSST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between anxiety and mitochondrial respiration</measure>
    <time_frame>Day 1</time_frame>
    <description>The association between mitochondrial respiration using extracellular flux analysis (Seahorse) on blood lymphocytes, and anxiety symptoms measured using the state and trait anxiety inventory (STAI), will be quantified by a linear regression across all study participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average neuropsychological function</measure>
    <time_frame>Day 2 neuropsychological session</time_frame>
    <description>Groups will be compared on the fluency/initiation domain of executive functioning assessed using the Delis-Kaplan Executive Function System (D-KEFS) test.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mitochondrial Diseases</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No diagnosis of mitochondrial disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants carrying the m.3243A&gt;G point mutation, without a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mutation with MELAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants carrying the m.3243A&gt;G point mutation, with a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants carrying a single, large-scale mtDNA deletion</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Trier social stress test</intervention_name>
    <description>The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.</description>
    <arm_group_label>Deletion</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Mutation</arm_group_label>
    <arm_group_label>Mutation with MELAS</arm_group_label>
    <other_name>TSST</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women patients between 18 and 55 years of age&#xD;
&#xD;
          -  Willing to provide saliva samples and have venous catheter installed for blood&#xD;
             collection during the hospital visit&#xD;
&#xD;
          -  Willing to provide informed consent and capacity to consent&#xD;
&#xD;
          -  Use of effective method of birth control for women of childbearing capacity&#xD;
&#xD;
          -  English Speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with cognitive deficit incapable of providing informed consent will not be&#xD;
             included&#xD;
&#xD;
          -  Symptoms of flu or other seasonal infection four weeks preceding hospital visit&#xD;
&#xD;
          -  Raynaud's syndrome (Raynaud phenomenon)&#xD;
&#xD;
          -  Involvement in any therapeutic trials listed on clinicaltrials.gov, including exercise&#xD;
&#xD;
          -  Metal inside or outside the body or claustrophobia prohibitive to MRI testing&#xD;
&#xD;
          -  Diagnosed with mitochondrial disease m.3243A&gt;G, or large scale mtDNA deletion (for&#xD;
             healthy controls)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Picard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Picard, PhD</last_name>
    <phone>6467748967</phone>
    <email>mp3484@columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Picard, PhD</last_name>
      <phone>646-774-8967</phone>
      <email>mp3484@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Picard, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michio Hirano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Sloan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Trumpff, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.picardlab.org/uploads/7/7/8/4/77845210/1_misbie_brochure_2018-06-26.pdf</url>
    <description>Study Brochure</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Martin Picard</investigator_full_name>
    <investigator_title>Associate Professor of Behavioral Medicine (in Psychiatry and Neurology)</investigator_title>
  </responsible_party>
  <keyword>Mitochondria</keyword>
  <keyword>Brain Imaging</keyword>
  <keyword>Psychophysiology</keyword>
  <keyword>Epigenetics</keyword>
  <keyword>Stress</keyword>
  <keyword>Metabolic rate</keyword>
  <keyword>Mitochondrial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be deposited to the NIMH Data Archive.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be made available at the end of the study, without a expiry date.</ipd_time_frame>
    <ipd_access_criteria>Access will be handled through the NIMH Data Archive (NDA)</ipd_access_criteria>
    <ipd_url>https://nda.nih.gov</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

